Stockscreener 앱 받기
0.2402
3.98%
0.0092
시간 외 거래:
.24
-0.0002
-0.08%
전일 마감가:
$0.231
열려 있는:
$0.2401
하루 거래량:
7,564
Relative Volume:
37.31
시가총액:
$N/A
수익:
-
순이익/손실:
$-13.24M
주가수익비율:
-0.0272
EPS:
-8.83
순현금흐름:
$-16.85M
1주 성능:
+3.98%
1개월 성능:
-94.94%
6개월 성능:
-97.91%
1년 성능:
-99.74%
1일 변동 폭
$0.24
$0.273
1주일 범위
$0.24
$0.273
52주 변동 폭
$0.212
$0.2869
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
VRPX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.2402 | 0 | 0 | -13.24M | -16.85M | -8.83 |
|
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Virpax Pharmaceuticals Inc 주식(VRPX)의 최신 뉴스
Best Nanotechnology Stocks To Follow Today – May 31st - Defense World
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading 4.4% Higher – Still a Buy? - Defense World
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax and Nanomerics Enter Technology License Agreement for Developing A Product for PTSD Treatment - StatNano
Promising Nanotechnology Stocks To Watch Now – May 7th - The AM Reporter
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading Up 5.5% – Here’s What Happened - Defense World
Virpax(R) Pharmaceuticals Announces Appointment of Michèle C. Linde, EVP, General Counsel - ACCESS Newswire
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Large Increase in Short Interest - Defense World
Virpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology Conference - MSN
Virpax Pharmaceuticals to be delisted from Nasdaq By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news - Investing.com India
Virpax Pharmaceuticals to be delisted from Nasdaq - Investing.com
Promising Nanotechnology Stocks To ResearchMarch 29th - MarketBeat
Promising Nanotechnology Stocks To Watch NowMarch 22nd - MarketBeat
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split By Investing.com - Investing.com Australia
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split - Investing.com India
VRPX stock plunges to 52-week low of $0.12 amid market challenges - Investing.com Australia
Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals - Business Wire
Virpax Pharmaceuticals announces 1-for-25 reverse stock split By Investing.com - Investing.com South Africa
VRPX stock plunges to 52-week low of $0.12 amid market challenges By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals announces 1-for-25 reverse stock split - Investing.com India
Virpax Pharmaceuticals Announces Reverse Stock Split - Business Wire
Virpax Reports Positive Results From Dose Range Finding Study of Pain Relief Treatment in Beagle Dogs - MarketScreener
Virpax receives positive Probudur(TM) results for dose range study -March 18, 2025 at 05:34 pm EDT - Marketscreener.com
Virpax reports positive results in Probudur dog study By Investing.com - Investing.com Australia
Virpax reports positive results in Probudur dog study - Investing.com
Breakthrough: Virpax's 5-Day Pain Drug Passes Critical Safety Test - StockTitan
Virpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using MET - MSN
Virpax Pharmaceuticals stock hits 52-week low at $0.18 By Investing.com - Investing.com Australia
Virpax Pharmaceuticals stock hits 52-week low at $0.18 - Investing.com
Nanotechnology Stocks To Follow Now – March 7th - Defense World
Virpax Looking To Use Met To Develop Intranasal Covid Vaccine -March 07, 2025 at 08:36 am EST - Marketscreener.com
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine - The Bakersfield Californian
Could This Needle-Free COVID Vaccine Technology Transform Vaccine Delivery? - StockTitan
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology - MSN
Can Virpax's Nasal Pain Treatment Solve the Opioid Addiction Problem? - StockTitan
Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS - Business Wire
Stock Market Update – Virpax Pharmaceuticals Stock Price Prediction 2025 - ldccbank
Virpax Pharmaceuticals Inc (VRPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
1.24%
자본화:
|
볼륨(24시간):